Illumina's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Illumina (ILMN)

Q1 2012 Earnings Call

April 23, 2012 5:00 pm ET


Kevin Williams -

Marc Stapley - Chief Financial Officer, Senior Vice President and Principal Accounting Officer

Jay T. Flatley - Chief Executive Officer, President and Director

Christian O. Henry - Senior Vice President and General Manager of Genomic Solutions


Tycho W. Peterson - JP Morgan Chase & Co, Research Division

Doug Schenkel - Cowen and Company, LLC, Research Division

Amanda Murphy - William Blair & Company L.L.C., Research Division

Derik De Bruin - BofA Merrill Lynch, Research Division

Daniel Brennan - Morgan Stanley, Research Division

Isaac Ro - Goldman Sachs Group Inc., Research Division

David C. Clair - Piper Jaffray Companies, Research Division

Nandita Koshal - Barclays Capital, Research Division

Daniel Arias - UBS Investment Bank, Research Division

Daniel L. Leonard - Leerink Swann LLC, Research Division

Jonathan P. Groberg - Macquarie Research

Quintin J. Lai - Robert W. Baird & Co. Incorporated, Research Division

Sung Ji Nam - Cantor Fitzgerald & Co., Research Division



Good day, ladies and gentlemen, and welcome to the First Quarter 2012 Illumina Incorporated Earnings Conference Call. My name is Charis, and I will be your coordinator for today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. And I would now like to hand the call over to your host for today, Mr. Kevin Williams. Please proceed.

Kevin Williams

Thank you very much. Good afternoon, everyone, and welcome to our earnings call for the first quarter of 2012. During the call, we will review our financial results released today after the close of market and offer commentary on our commercial activity after which, we will host a question-and-answer session. If you have not had a chance to review the earnings release, it can be found in the Investor Relations section of our website at

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement